Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06374641
Other study ID # 5514255
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 26, 2024
Est. completion date August 2025

Study information

Verified date May 2024
Source University of Exeter
Contact Jimmy T Wangdi, PhD
Phone 441392 661000
Email j.Wangdi4@exeter.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the effects of taking a new supplement for 16 days on cognitive function and exercise performance, compared to a placebo (a supplement that looks and tastes the same, but doesn't have the same ingredients) in 40 healthy individuals - 20 young individuals (aged 18-30) and 20 older individuals (aged 50-65). The main questions it aims to answer are: - If taking the supplement for 16 days improves exercise performance, or the speed with which the body responds to the commencement of exercise. - If taking the supplement improves cognitive function. Participants will visit the lab on 5 separate occasions to: - complete some cognitive tests - complete exercise performance tests - provide blood samples All exercise tests will be on an exercise bike. After 28 (or 46 for pre-menopausal females) days to make sure the supplement has left the body fully, participants will consume the opposite supplement and repeat the tests.


Description:

This study is a randomised, placebo-controlled, cross-over trial investigating the effects of supplementing with a novel mitochondrial substrate supplement on exercise performance and cognitive function. The supplement is composed of three bioactive components: choline, nicotinamide and succinate. All three components are available on the market as supplements and/or as food additives, but have not previously been combined. This study will recruit 40 individuals in two cohorts. The first cohort will consist of 20 young individuals (aged 18-30) and the second cohort will consist of 20 older individuals (aged 50-65). Individuals will be block randomised into two groups within each cohort, taking either the placebo or supplement first. Trials will be counterbalanced by Latin square to remove any trial-order effect. This study will involve 5 lab visits per participant, including a familiarisation visit and a further 2 visits per trial arm. Familiarisation will consist of questionnaires and cognitive tests, warm-up and ramp incremental test on a cycle ergometer for all participants. The ramp incremental test will commence with a 3-minute unloaded baseline period followed by an increase in work rate until task failure. Task failure will be defined as a drop by >10 rpm below participants' self-selected cadence (which is expected to lie between 70 and 100 rpm). Following a rest period, participants in the 'young' cohort will also complete a 3-minute all-out test on a cycle ergometer. Participants will be supplemented with 65 mL.d-1 of either a placebo or the supplement twice daily for 16 days while recording food intake and exercise activities. On days 15 and 16 of supplementation, participants will return to the lab for testing. Testing on day 15 will consist of questionnaires and cognitive tests, a venous blood sample, and a 3-minute all out test (young cohort) or ramp incremental test (older cohort) on a cycle ergometer. Venous samples will be collected prior to exercise. Testing on day 16 will consist of a series of three 6-min step tests, from unloaded to moderate intensity, with a 15-minute rest period between each test. Moderate exercise is defined as exercise which occurs below the lactate threshold. Participants will then complete an intermittent exercise protocol consisting of alternating 60-second periods of severe intensity exercise and 30-second periods of recovery until they reach the limit of tolerance. Severe intensity is defined as exercise which occurs above the critical power, where VO2max is reached at exhaustion. All tests will be conducted on a cycle ergometer. Following completion of the first trial arm, participants will undergo a 28 or 46 (pre-menopausal females) day washout period. The washout period for young female participants is adjusted to enable all testing to occur in the same phase of the menstrual cycle and thus remove potential associated confounding effects. Participants will then repeat the supplementation protocol and testing visits on days 15 and 16 with the opposing supplement.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date August 2025
Est. primary completion date April 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participants will be deemed eligible to participate provided they are willing and able to follow the study instructions and 1. are able to take part in intense exercise (as assessed via Physical Activity Readiness Questionnaire (PARQ)) 2. are able to consume a dietary supplement 3. are not overweight/obese (assessed by BMI) 4. do not have any cardiovascular, respiratory, metabolic or musculoskeletal disorders, or any other contraindication to the performance of maximal exercise. Exclusion Criteria: 1. Aged 31-49 and aged 66+. 2. underlying illness or injury (assessed via PARQ) 3. overweight or obese individuals (BMI of >30 kg.m-2). 4. Cardiovascular, respiratory, metabolic or musculoskeletal disorders (assessed by screening form). 5. Use of dietary supplements, tobacco smoking. 6. Pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Mitochondrial Substrate Supplement
Mitochondrial Substrate supplement, 2xdaily 65 mL drink
Placebo Supplement
Placebo supplement, 2xdaily 65 mL drink

Locations

Country Name City State
United Kingdom Richards Building St. Lukes Campus University of Exeter Exeter Devon

Sponsors (3)

Lead Sponsor Collaborator
University of Exeter Innovate UK, Mitocholine Ltd

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, Tarr J, Benjamin N, Jones AM. Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J Appl Phys — View Citation

Chidnok W, Dimenna FJ, Bailey SJ, Vanhatalo A, Morton RH, Wilkerson DP, Jones AM. Exercise tolerance in intermittent cycling: application of the critical power concept. Med Sci Sports Exerc. 2012 May;44(5):966-76. doi: 10.1249/MSS.0b013e31823ea28a. — View Citation

Vanhatalo A, Doust JH, Burnley M. Determination of critical power using a 3-min all-out cycling test. Med Sci Sports Exerc. 2007 Mar;39(3):548-55. doi: 10.1249/mss.0b013e31802dd3e6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise Capacity Exercise performance as measured by ramp incremental test (older group) or 3 minute all out test (young group) and intermittent exercise test. The ramp incremental cycling test is well-established for the determination of maximal oxygen uptake (VO2max) and gaseous exchange threshold, which are key markers of cardiorespiratory health and predictor of endurance exercise performance. The 3 minute all out test is commonly used to determine critical power and W'. The critical power represents the highest power output an individual can sustain while remaining in an aerobic steady state, and the W' represents the anaerobic capacity.
The intermittent test consists of intermittent exercise in which 1 min of severe intensity exercise is alternated with 30 s of lower intensity exercise until the participant reaches their limit of tolerance. Time to exhaustion allows for assessment of exercise capacity.
Day 15 and 16
Primary VO2 kinetic response to exercise The VO2 response measured during step test from unloaded to moderate intensity exercise. The participant will cycle against a low resistance and then the resistance on the pedals will be increased abruptly to provide a moderate-intensity work rate which will be maintained for 6 minutes. The VO2 response will then be examined from the onset of exercise to the attainment of a steady state. The VO2 responses to the three step tests will be averaged and modelled to provide information on the rate at which the muscle mitochondria use oxygen to supply energy to meet the demands of the exercise. The steady-state VO2 value for the imposed work rate also allows for the assessment of exercise economy. Day 16
Primary Cognitive Function (Stroop test) Cognitive function tested via Stroop test administered by computerised system. Day 15
Primary Cognitive Function (decision reaction test) Cognitive function tested via decision reaction test administered by computerised system. Day 15
Primary Grip Strength Grip strength measured by hand strength dynamometer. Day 15
Secondary Capillary Blood Lactate Capillary Blood Lactate used during step tests and intermittent exercise tests to examine the production of lactate and inferred levels of muscle acidosis. Before and after each step during the step test, and before and after every 2 exercise bouts during the intermittent exercise protocol.
Secondary Questionnaire 1 To assess participant experience during the supplementation period and study protocol with regard to factors such as fatigue, stress, sleep and perceived effort. Day 16
Secondary Questionnaire 2 To assess participant experience of the supplement with regard to factors such as perceived effects, tolerance and taste. Day 15
Secondary Venous Blood [Betaine] Assessment of Venous Blood [Betaine]. Day 15
Secondary Venous Blood [Choline] Assessment of Venous Blood [Choline]. Day 15
Secondary Venous blood [S-Adenosyl methionine] Assessment of Venous Blood [S-Adenosyl methionine]. Day 15
Secondary Venous blood [glucose]. Assessment of Venous Blood [glucose]. Day 15
Secondary Venous blood [insulin]. Assessment of Venous Blood [insulin]. Day 15
Secondary Venous blood [trimethylamine N-oxide]. Assessment of Venous Blood [triglycerides]. Day 15
See also
  Status Clinical Trial Phase
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT03708692 - Menstrual Cycle Phases on Recovery and Cognitive Function
Active, not recruiting NCT04505345 - Virtual Reality Cognitive Training in Alcohol Use Disorder N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT02915913 - Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults N/A
Completed NCT01410097 - Physical and Cognitive Function - Look AHEAD Ancillary Study N/A
Completed NCT03826121 - Efficacy and Safety of Sesame Oil Cake Extract on Improvement of Cognitive Function N/A
Recruiting NCT05621278 - Children to Adults Mental and Psychosomatic Health Study (CAMPS)
Completed NCT05498415 - Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study N/A
Completed NCT03208569 - Anticholinergic Burden - Treatment Optimization
Completed NCT03793777 - The Effect of Aronia Melanocarpa Extract on Cognitive Function N/A
Recruiting NCT05525299 - Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors N/A
Completed NCT03698123 - Performance Nutrition for Residents and Fellows N/A
Completed NCT04543500 - Self-regulation of Prefrontal Cortex During Emotional Cognitive Control N/A
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Recruiting NCT05591885 - Nutrilite Memory Builder on the Improvement of Cognitive Function N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT03716609 - Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function N/A
Completed NCT02763514 - The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood N/A
Completed NCT02675621 - Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults N/A